Company Profile

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The Company's clinical pipeline products include: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Employees

147

Sector

Biotechnology & Medical Research

More about the company

25-05-26	Gamida Cell Ltd. cancelled the acquisition of bluebird bio, Inc. from BlackRock, Inc., The Vanguard Group, Inc. and others.	CI
24-07-22	HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO	MT
24-06-18	Gamida Cell Names Rory Nealon as Chief Financial Officer	CI
24-06-18	Gamida Cell Names Sheila Frame as Chief Commercial Officer	CI
24-06-18	Gamida Cell Ltd. Names Joe Wiley as Chief Executive Officer	CI
24-06-17	Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC	CI
24-05-23	Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-04-09	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI
24-04-04	Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	CI
24-03-28	Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	MT
24-03-28	Top Premarket Decliners	MT
24-03-27	Top Midday Decliners	MT
24-03-27	Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	MT

24-01-29	JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	MT
23-11-15	Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	MT
23-11-15	HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	MT
23-05-19	JMP Securities Adjusts Price Target on Gamida Cell to $6 From $8, Keeps Market Outperform Rating	MT
23-05-16	Oppenheimer Adjusts Gamida Cell Price Target to $6 From $8, Maintains Outperform Rating	MT

24-03-27	Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management	AQ
24-03-27	Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update	AQ
24-03-22	Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results	AQ
24-02-23	Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®	AQ
24-01-29	Gamida Cell Actively Pursuing Strategic Alternatives	AQ

3 years	0.01	0.96
5 years	0.01	4.72
10 years	0.01	15.41

Manager	Title	Age	Since
Joe Wiley CEO	Chief Executive Officer	55	-
Heayoung Shin CTO	Chief Tech/Sci/R&D Officer	-	2021-05-31
Rory Nealon COO	Chief Operating Officer	59	2024-05-23

Gamida Cell Ltd. Stock

Stocks

GMDA

IL0011552663

Biotechnology & Medical Research

Latest news: Gamida Cell Ltd.

Analysts' recommendations: Gamida Cell Ltd.

Press Releases: Gamida Cell Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Gamida Cell Ltd.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Director	Title	Age	Since
Joe Wiley CHM	Chairman	55	-
George Hampton BRD	Director/Board Member	56	2019-03-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/31/24	Ronit Simantov	Free	Chief Technology Officer	480,319	0.3621%
1/31/24	Ivan Borrello	Free	Director	200,000	0.1508%
1/31/24	Kenneth Moch	Free	Director	200,000	0.1508%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GAMIDA CELL LTD.	+2.41%	-.--%	-	-	2.62M
WUXI APPTEC CO., LTD.	+2.41%	+0.29%	+42.02%	+71.57%	64.69B
ARGENX SE	-0.15%	+7.50%	+11.01%	+73.48%	54.78B
LONZA GROUP AG	+0.57%	+4.60%	+10.07%	+92.86%	53.49B
IQVIA HOLDINGS INC.	+0.37%	+4.67%	+27.03%	+52.07%	45.98B
BEONE MEDICINES AG	-1.21%	+2.32%	+21.80%	+123.81%	42.94B
REVOLUTION MEDICINES, INC.	-0.37%	+5.07%	+249.91%	+918.74%	40.08B
CELLTRION, INC.	+0.05%	+0.21%	+18.26%	+58.53%	33.52B
GENMAB A/S	-0.38%	+5.68%	+36.43%	+27.54%	23.67B
WUXI BIOLOGICS (CAYMAN) INC.	+1.19%	-4.98%	+29.01%	-0.65%	23.97B
Average	+0.49%	+2.41%	+49.51%	+157.55%	42.57B
Weighted average by Cap.	+0.39%	+2.73%	+47.57%	+158.58%